Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

B-Cell Depletion and Efficacy Outcomes of Ofatumumab Are Consistent Across Different Body Mass Index Categories: Insights from ASCLEPIOS I and II Trials

Author:Cross, Anne   Hauser, Stephen   Wiendl, Heinz   Bar-Or, Amit   Coyle, Patricia   Montalban, Xavier   De Seze, Jerome   Fu, Haoyi   Bhatt, Alit   Boer, Ibolya   Kappos, Ludwig   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.002  

Author Institution:Washington University School of Medicine, Saint Louis, MO, USA, Clayton, MO  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA  University of Münster, Münster, Germany, Muenster, Germany  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA, Philadelphia, PA  Department of Neurology, Stony Brook University, Stony Brook, NY, USA, Stony Brook, NY  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Headorgans, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland